Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal

[News]

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

More... (http://www.news-medical.net/news/20100517/Hawthorn-announces-licensing-deal-with-University-of-Pittsburgh-for-novel-monoclonal-antibodies-for-cancer.aspx)